Teledermatology cuts time to clinical resolution by 26 days

Teledermatology for suspected skin cancer costs more than usual care—but it speeds up the time to clinical resolution by nearly a month, according to a study published online May 9 in JAMA Dermatology.

Teledermatology has the potential of reaching more patients than tradition care, but research into its economic impacts are lacking. In this study, researchers evaluated the cost-effectiveness of teledermatology as a referral mechanism for skin cancer diagnosis and management in Australia.

“At present, there are no published economic evaluations for teledermoscopy services specific to the Australian health care system, and there are few international studies available,” wrote lead author Centaine L. Snoswell, MPH, from the University of Queensland in Woolloongabba, Australia. “The implementation of new models of care requires information on their comparative cost-effectiveness.”

 

The research team compared the costs of an electronic referral with digital dermoscopic images to a written referral letter. They found teledermatology costs an average of $318.39, compared to $263.75 for usual care. While the cost per person was higher, physicians achieved clinical resolution an average of 26 days earlier for teledermatology patients.

“Using teledermoscopy for skin cancer referral and triage in Australia would cost $54.64 extra per case on average but would result in clinical resolution 26 days sooner than usual care,” wrote Snoswell and colleagues. “Implementation recommendations depend on the preferences of the Australian health system decision makers for either lower cost or expedited clinical resolution. Further research around the clinical significance of expedited clinical resolution and its importance for patients could inform implementation recommendations for the Australian setting.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.